GUD Archives - BioTuesdays

Developments

Profound regains distribution rights for TULSA-PRO in Canada

Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) has announced that it has regained exclusive distribution rights for TULSA-PRO in Canada from Knight Therapeutics (TSX: GUD). Under the agreement established with Knight...

November 11, 2025

Developments

Knight files NDS for CREXONT in Canada

Knight Therapeutics (TSX: GUD) has announced that its new drug submission (NDS) for CREXONT—a novel, oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules for the treatment of Parkinson’s disease—has...

July 18, 2025

Markets

Mackie ups Knight Therapeutics to buy; PT to $10.80 from $8.20

Mackie Research Capital upgraded Knight Therapeutics (TSX:GUD) to “buy” from “hold” and raised its price target to $10.80 from $8.20 after Knight’s planned acquisition of Grupo Biotoscana for $369-million (Canadian)...

October 23, 2019

Developments

Knight expands reimbursement for Titan Pharma’s Probuphine in Canada

Knight Therapeutics (TSX:GUD) reached agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for a letter of intent covering reimbursement of Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine, the first...

August 6, 2019

Markets

RBC starts Knight Therapeutics at OP; PT $9.50

RBC Capital Markets launched coverage of Knight Therapeutics (TSX:GUD) with an “outperform” rating and price target of $9.50. The stock closed at $7.79 on April 20. Knight’s focus is on the licensing and...

April 23, 2018

Developments

Titan Pharma’s Probuphine implant for long-term maintenance treatment of opioid dependence approved by Health Canada

Health Canada has approved the sale of Probuphine, a subdermal implant developed by Titan Pharmaceuticals (NASDAQ:TTNP), for the management of opioid dependence in patients clinically stabilized on no more than 8 mg of...

April 20, 2018

Feature

Knight Therapeutics “to get real” as it builds its commercial operations

By Len Zehr In the more than 30 months since its startup, Knight Therapeutics (TSX:GUD) has shown an uncanny knack for raising equity at increasing valuations, building a portfolio of some 20 innovative products for its...

September 20, 2016

Feature

Knight won’t rest til it bests Paladin

By Len Zehr “It is entirely the goal of Knight Therapeutics (TSX:GUD) to duplicate the success of Paladin Labs,” says president and CEO, Jonathan Ross Goodman, who turned Paladin into a premier distributor of specialty...

May 13, 2014

Tag - GUD

Profound regains distribution rights for TULSA-PRO in Canada

Knight files NDS for CREXONT in Canada

Mackie ups Knight Therapeutics to buy; PT to $10.80 from $8.20

Knight expands reimbursement for Titan Pharma’s Probuphine in Canada

RBC starts Knight Therapeutics at OP; PT $9.50

Titan Pharma’s Probuphine implant for long-term maintenance treatment of opioid dependence approved by Health Canada

Knight Therapeutics “to get real” as it builds its commercial operations

Knight won’t rest til it bests Paladin

Subscribe